Copanlisib: First Global Approval

Anthony Markham
Compliance with Ethical Standards
Funding: The preparation of this review was not supported by any external funding.
Conflicts of interest: A. Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found here.
Bayer are developing copanlisib (Aliqopa™) – a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor – as a treatment for various haematological and solid malignancies. The US FDA has...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.